Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tecovirimat 是一种核心蛋白半胱氨酸蛋白酶抑制剂,可能用于治疗天花感染。Tecovirimat 是一种新型抗病毒药物,对多种正痘病毒具有有效和选择性的活性(EC50:约 10 nM)。通过靶向病毒 p37 蛋白直系同源物来抑制正痘病毒的排出。迄今为止,Tecovirimat 已在所有小动物和非人类灵长类动物预防和治疗痘病毒引起的疾病模型中显示出功效。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,152 | 现货 | ||
5 mg | ¥ 2,357 | 现货 | ||
10 mg | ¥ 3,527 | 现货 | ||
25 mg | ¥ 6,987 | 现货 | ||
50 mg | ¥ 10,587 | 现货 | ||
100 mg | ¥ 15,877 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,447 | 现货 |
产品描述 | Tecovirimat is a core protein cysteine protease inhibitor potentially for treatment of smallpox infection.Tecovirimat is a novel antiviral potent and selective activity against multiple orthopoxviruses (EC50: about 10 nM). that inhibits the egress of orthopoxviruses by targeting viral p37 protein orthologs.Tecovirimat has shown efficacy in all small animal and nonhuman primate prophylaxis and therapeutic efficacy models of poxvirus-induced disease tested to date. |
体外活性 |
ST-246 was evaluated for activity against cowpox virus (CV), vaccinia virus (VV), and ectromelia virus (ECTV) and had an in vitro 50% effective concentration (EC50) of 0.48 microM against CV, 0.05 microM against VV, and 0.07 microM against ECTV.?The selectivity indices were >208 and >2,000 for CV and VV, respectively.?The in vitro antiviral activity of ST-246 was significantly greater than that of cidofovir, which had an EC50 of 41.1 microM against CV and 29.2 microM against VV, with selectivity indices of >7 and >10, respectively[2]. |
体内活性 |
ST-246 administered once daily by oral gavage to mice infected intranasally with CV beginning 4 h or delayed until 72 h postinoculation was highly effective when given for a 14-day duration using 100, 30, or 10 mg/kg of body weight.?When 100 mg/kg of ST-246 was administered to VV-infected mice, a duration of 5 days was sufficient to significantly reduce mortality even when treatment was delayed 24 h postinoculation.?Viral replication in liver, spleen, and kidney, but not lung, of CV- or VV-infected mice was reduced by ST-246 compared to levels for vehicle-treated mice.?When 100 mg/kg of ST-246 was given once daily to mice infected by the intranasal route with ECTV, treatment for 10 days prevented mortality even when treatment was delayed up to 72 h after viral inoculation.?Viral replication in target organs of ECTV-infected mice was also reduced[2]. |
别名 | ST-246, 特考韦瑞 |
分子量 | 376.33 |
分子式 | C19H15F3N2O3 |
CAS No. | 869572-92-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (132.86 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6572 mL | 13.2862 mL | 26.5724 mL | 66.4311 mL |
5 mM | 0.5314 mL | 2.6572 mL | 5.3145 mL | 13.2862 mL | |
10 mM | 0.2657 mL | 1.3286 mL | 2.6572 mL | 6.6431 mL | |
20 mM | 0.1329 mL | 0.6643 mL | 1.3286 mL | 3.3216 mL | |
50 mM | 0.0531 mL | 0.2657 mL | 0.5314 mL | 1.3286 mL | |
100 mM | 0.0266 mL | 0.1329 mL | 0.2657 mL | 0.6643 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tecovirimat 869572-92-9 Proteases/Proteasome Cysteine Protease ST-246 ST 246 特考韦瑞 ST246 Inhibitor inhibitor inhibit